In Vitro Diagnostics - Niger | Statista Market Forecast

The projected revenue in the In Vitro Diagnostics market market in Niger is estimated to reach US$12.37m in 2024.
With an expected annual growth rate (CAGR 2024-2029) of 5.68%, the market volume is predicted to reach US$16.30m by 2029.
It is worth noting that in global comparison, the United States is expected to generate the highest revenue in this market, reaching US$30.10bn in 2024.
Niger's In Vitro Diagnostics market is experiencing a growing demand for point-of-care testing due to its vast rural areas and limited healthcare infrastructure.

Definition:
The market In Vitro Diagnostics (IVD) consists of medical instruments and accessories used to perform tests with the help of biological samples. In Vitro Diagnostics provide valuable information used for detection, prognosis, prevention, and therapeutic monitoring of diseases.

Additional information:
Market values represent revenues paid to primary vendors at manufacturer price level either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), enterprises (B2B) as well as governments (B2G). Revenues are allocated to the country where the money is spent.

Company examples: Roche Diagnostics, Abbott Laboratories, Danaher, Siemens Healthineers.
Further information on the key players can be found in the Market Shares boxes.

Molecular diagnosis
Immunoassays
Clinical chemistry
Microbiology
Hematology

Services (i.e., treatment expenses)
Imaging diagnostics

The In Vitro Diagnostics market in Niger is experiencing significant growth due to customer preferences, trends in the market, local special circumstances, and underlying macroeconomic factors. Customer preferences in Niger are driving the growth of the In Vitro Diagnostics market. There is a growing demand for diagnostic tests that can provide accurate and timely results. Customers in Niger are increasingly seeking diagnostic tests that can detect diseases at an early stage, allowing for more effective treatment and management. Additionally, there is a preference for diagnostic tests that are affordable and accessible to the general population. Trends in the market are also contributing to the growth of the In Vitro Diagnostics market in Niger. One of the key trends is the increasing adoption of point-of-care testing. This type of testing allows for immediate results, eliminating the need for samples to be sent to a laboratory for analysis. Point-of-care testing is particularly beneficial in remote areas where access to healthcare facilities may be limited. Another trend in the market is the development of innovative diagnostic tests that can detect multiple diseases or conditions simultaneously. These multiplex tests are more efficient and cost-effective, making them highly desirable in the Niger market. Local special circumstances in Niger are playing a role in the development of the In Vitro Diagnostics market. The country has a high burden of infectious diseases, such as malaria and HIV/AIDS. As a result, there is a strong demand for diagnostic tests that can accurately detect these diseases. Additionally, the healthcare infrastructure in Niger is still developing, with limited laboratory capacity in certain areas. This creates a need for diagnostic tests that can be easily performed in decentralized settings. Underlying macroeconomic factors are also driving the growth of the In Vitro Diagnostics market in Niger. The country has been experiencing steady economic growth, which has led to an increase in healthcare spending. This has allowed for greater investment in healthcare infrastructure and the procurement of advanced diagnostic equipment. Furthermore, the government of Niger has recognized the importance of healthcare and has implemented policies to improve access to quality healthcare services. These efforts have contributed to the growth of the In Vitro Diagnostics market in the country. In conclusion, the In Vitro Diagnostics market in Niger is experiencing significant growth due to customer preferences, trends in the market, local special circumstances, and underlying macroeconomic factors. The demand for accurate and accessible diagnostic tests, the adoption of point-of-care testing, the development of innovative multiplex tests, the high burden of infectious diseases, the limited laboratory capacity, the steady economic growth, and the government's focus on healthcare are all contributing to the growth of the market in Niger.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on medical devices and IVD revenues allocated to the country where the money is spent at manufacturer price levels excluding VAT.

Modeling approach / Market size:

Modeling employs a top-down approach with a bottom-up validation, using financial information of the key players by market. Market sizes are determined by a top-down approach, based on a specific rationale for each market market and allocated to the covered countries according to the global market shares. As a basis for evaluating markets, we use relevant key market indicators and data from country-specific associations, such as healthcare expenditure per capita, health risk factors, healthcare system, and regulations concerning medical products. Next, we use further relevant key market indicators and data from country-specific associations, such as healthcare expenditure per capita, health risk factors, healthcare payer system, and regulations concerning medical products. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

Medical technology plays a role in the lives of everyone. It includes most of all, medical devices which simplify the prevention, diagnosis, and treatment of diseases and illnesses. The most well-known medical technology products are, among others, pacemakers, imaging instruments, dialysis machines, and implants. The global medical technology industry was worth over 567 billion U.S. dollars annually. Established centers of this industry include North America and Western Europe. The United States is home to the world’s largest medical technology companies. As of 2022, Abbott Laboratories had the largest global revenue at over 31.2 billion U.S. dollars. The main focus of devices manufactured by the Chicago-based company are diagnostics, cardiovascular, and diabetes care. Two other medtech companies that round off the top three largest companies –Medtronic and Johnson & Johnson – are both based in the United States. Although, industry trends show that Asia, and in particular China, is about to play a more prominent role in the years to come.